Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been approved for the treatment of metastatic renal cell carcinoma (mRCC). However, the response rate is still limited, and it is urgent to pursue novel and concise markers of responses to ICIs that allow the determination of clinical benefits. Re...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumura, Soichi, Kato, Taigo, Kujime, Yuma, Kitakaze, Hiroaki, Nakano, Kosuke, Hongo, Sachiko, Yoshioka, Iwao, Okumi, Masayoshi, Nonomura, Norio, Takada, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257831/
https://www.ncbi.nlm.nih.gov/pubmed/37301837
http://dx.doi.org/10.1186/s12894-023-01248-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257831/
https://www.ncbi.nlm.nih.gov/pubmed/37301837
http://dx.doi.org/10.1186/s12894-023-01248-z

Ejemplares similares